Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Freya Pharma","sponsor":"Emotional Brain BV","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Freya Pharma Solutions to Acquire All IP From Emotional Brain, Giving Opportunities to Further Examine Pharmaceutical Therapies for Female Sexual Interest\/Arousal Disorder in A Double Blind, Randomized Phase 3 Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Freya Pharma Solutions Secures US$8.5 Million Enabling the Start of A Pivotal Phase 3 Trial with Lybrido Against Female Sexual Interest\/Arousal Disorder (FSIAD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Announced Its Application for EMA Scientific Advice on its Phase 3 Clinical Trial to Confirm Efficacy of Lybrido in Women Suffering From FSIAD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Announced Further Strengthening of its IP Position for Improved Treatment for Women Suffering From FSIAD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Appoints Nicole Hijnen as President of The Board, Overseeing the Company's Upcoming Clinical Development Program With Lybrido\u2122 Against FSIAD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Announces Advice from the FDA on its US Clinical Development Program of Lybrido\u2122 for the treatment of Female Sexual Interest\/Arousal Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Announces Response from the FDA on its US Clinical Development Program of LybridoTM for the treatment of Female Sexual Interest\/Arousal Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Freya Pharma

    Menu

    Freya Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Freya Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Freya Pharma Solutions Announces Response from the FDA on its US Clinical Development Program of LybridoTM for the treatment of Female Sexual Interest/Arousal Disorder

              Details:

              Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil that used for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD).

              Lead Product(s): Sildenafil Citrate,Testosterone

              Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Freya Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Freya Pharma Solutions Announces Advice from the FDA on its US Clinical Development Program of Lybrido™ for the treatment of Female Sexual Interest/Arousal Disorder

              Details:

              Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil. It increases central sexual motivation and physiological sexual responses.

              Lead Product(s): Sildenafil Citrate

              Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Freya Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Freya Pharma Solutions Appoints Nicole Hijnen as President of The Board, Overseeing the Company's Upcoming Clinical Development Program With Lybrido™ Against FSIAD

              Details:

              Lybrido (sildenafil) intends to increase central sexual motivation and physiological sexual responses. It consists of a novel combination tablet containing a testosterone coating for sublingual administration and an inner-core component made of the PDE-5 inhibitor, sildenafil.

              Lead Product(s): Sildenafil Citrate

              Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Freya Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Freya Pharma Solutions Announced Further Strengthening of its IP Position for Improved Treatment for Women Suffering From FSIAD

              Details:

              Lybrido (sildenafil) is a unique therapeutic concept, both by its combination of testosterone and sildenafil, as well as by its dual route, dual release, fixed dose system, and as such achieving the optimal synergy of both active ingredients.

              Lead Product(s): Sildenafil Citrate

              Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Freya Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Freya Pharma Solutions Announced Its Application for EMA Scientific Advice on its Phase 3 Clinical Trial to Confirm Efficacy of Lybrido in Women Suffering From FSIAD

              Details:

              Lybrido (sildenafil) increases central sexual motivation and physiological sexual responses, such as swelling of vaginal erectile tissue and lubrication.

              Lead Product(s): Sildenafil Citrate

              Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Freya Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Freya Pharma Solutions Secures US$8.5 Million Enabling the Start of A Pivotal Phase 3 Trial with Lybrido Against Female Sexual Interest/Arousal Disorder (FSIAD)

              Details:

              The new funding will be used to carry out a pivotal phase 3 trial with its therapy Lybrido in 516 patients across Europe. Lybrido showed clinical relevance and statistical significance in a phase 2b clinical trial, clearly meeting the primary endpoints.

              Lead Product(s): Sildenafil Citrate

              Therapeutic Area: Psychiatry/Psychology Product Name: Lybrido

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $8.5 million Upfront Cash: Undisclosed

              Deal Type: Financing March 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Freya Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Freya Pharma Solutions to Acquire All IP From Emotional Brain, Giving Opportunities to Further Examine Pharmaceutical Therapies for Female Sexual Interest/Arousal Disorder ...

              Details:

              Freya Pharma has been established to further advance two compounds for the FSIAD-disorder, Lybrydo and Lybrydos, that have shown clinical and statistical relevance in an earlier phase 2b clinical trial, clearly meeting the primary endpoints.

              Lead Product(s): Sildenafil Citrate,Testosterone

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Lybrido

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Emotional Brain BV

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition December 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY